BK-5-MAPBT

BK-5-MAPBT
Clinical data
Other names	bk-5-MAPBT; β-Keto-5-MAPBT
Drug class	Monoamine releasing agent; Serotonin 5-HT1B receptor agonist; Entactogen
ATC code	None;
Identifiers
	IUPAC name 1-(1-benzothiophen-5-yl)-2-(methylamino)propan-1-one;
CAS Number	2106849-09-4;
PubChem CID	165949396;
ChemSpider	72779382;
Chemical and physical data
Formula	C12H13NOS
Molar mass	219.30 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C(=O)C1=CC2=C(C=C1)SC=C2)NC;
	InChI InChI=1S/C12H13NOS/c1-8(13-2)12(14)10-3-4-11-9(7-10)5-6-15-11/h3-8,13H,1-2H3; Key:UUTCAMGZEOYTDB-UHFFFAOYSA-N;

BK-5-MAPBT, also known as β-keto-5-MAPBT, is a possible entactogen of the benzothiophene and cathinone families.^[1] It is a potent monoamine releasing agent, including of serotonin and dopamine, and also acts as a potent serotonin 5-HT_1B receptor agonist.^[1] Conversely, norepinephrine release was not reported.^[1] Unlike non-cathinone benzothiophenes like 5-MAPBT and 6-MAPBT, BK-5-MAPBT is very weak or inactive as a serotonin 5-HT_2B receptor antagonist and monoamine oxidase A (MAO-A) inhibitor.^[1] It produces anxiolytic-like and antiobsessional-like effects in the marble burying test in rodents.^[1] BK-5-MAPBT has been studied and patented by Matthew J. Baggott of Tactogen.^[1]